Crosstalk between the angiotensin and endothelin-system in the cerebrovasculature

Juergen Konczalla1, Stefan Wanderer, Jan Mrosek

  • 1Department of Neurosurgery, Johann Wolfgang Goethe-University Frankfurt am Main, Schleusenweg 2- 16, 60528 Frankfurt am Main, Germany. J.Konczalla@med.uni-frankfurt.de.

Insights

Losartan, an AT1-receptor blocker, reduces endothelin-1 induced contraction in rat basilar arteries, potentially mitigating cerebral vasospasm after subarachnoid hemorrhage.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cardiovascular Research

Background:

  • Subarachnoid hemorrhage (SAH) leads to poor outcomes due to multifactorial processes like inflammation and cerebral vasospasm (CVS).
  • Losartan shows potential benefits in SAH by preventing CVS and reducing brain injury, but its precise mechanism on cerebrovascular contractility is unclear.
  • Angiotensin II's role in cerebrovascular function post-SAH is not fully understood, particularly concerning AT1-receptor activity.

Purpose of the Study:

  • To investigate the functional interaction between AT1-receptor blockade by losartan and endothelin-1 (ET-1) mediated vasoconstriction and vasorelaxation.
  • To elucidate the role of losartan in modulating ET-1's effects on the rat basilar artery.

Main Methods:

  • Organ bath experiments were conducted to assess vasoreactivity of rat basilar arteries.
  • Experiments involved incubation with losartan, ET(B)-receptor antagonist (BQ-788), and ET(A)-receptor antagonist (BQ-123).
  • Changes in ET-1 induced contraction and relaxation were measured under various conditions.

Main Results:

  • Losartan significantly decreased ET-1 induced contraction in the basilar artery.
  • This decreased contraction was abolished by BQ-788, indicating an ET(B)-receptor dependent mechanism.
  • Losartan, combined with BQ-123, resulted in enhanced ET-1 induced relaxation, suggesting AT1-receptor antagonism modulates ET(B)-receptor vasorelaxation.
  • Losartan upregulated the NO-pathway, increasing relaxation and ET(B)-receptor sensitivity.

Conclusions:

  • AT1-receptor antagonism by losartan exerts a modulatory effect on ET(B)-receptor dependent vasorelaxation in the basilar artery.
  • Losartan demonstrates a dose-dependent antagonistic effect on ET-1 induced contraction, primarily via ET(B)-receptors.
  • These findings suggest a novel beneficial mechanism for losartan in SAH, complementing its known effects on CVS, autoregulation, and brain injury.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Neural Regulation of Blood Pressure01:18

Neural Regulation of Blood Pressure

The neural regulation of blood pressure involves intricate interactions between the autonomic nervous system (ANS) and cardiovascular system, ensuring adequate perfusion of tissues. This regulation primarily occurs through baroreceptor and chemoreceptor reflexes, involving both short-term and long-term mechanisms.
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...